About the Authors
- Shih-Wen Lin
-
* E-mail: lins4@mail.nih.gov
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Arpita Ghosh
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Carolina Porras
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Sarah C. Markt
-
Affiliation Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
- Ana Cecilia Rodriguez
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Mark Schiffman
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Sholom Wacholder
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Troy J. Kemp
-
Affiliation HPV Immunology Laboratory, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland, United States of America
- Ligia A. Pinto
-
Affiliation HPV Immunology Laboratory, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland, United States of America
- Paula Gonzalez
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Nicolas Wentzensen
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Mark T. Esser
-
Affiliation MedImmune, Gaithersburg, Maryland, United States of America
- Katie Matys
-
Affiliation PPD Vaccines and Biologics Center of Excellence, Wayne, Pennsylvania, United States of America
- Ariane Meuree
-
Affiliation GlaxoSmithKline Biologicals, Rixensart, Belgium
- Wim Quint
-
Affiliation DDL Diagnostic Laboratory, Voorburg, The Netherlands
- Leen-Jan van Doorn
-
Affiliation DDL Diagnostic Laboratory, Voorburg, The Netherlands
- Rolando Herrero
-
Affiliation Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France
- Allan Hildesheim
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Mahboobeh Safaeian
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Costa Rican Vaccine Trial Group
-
¶Membership of the Costa Rican Vaccine Trial Group is provided in the Acknowledgments
Competing Interests
This study was conducted with the support from the Ministry of Health of Costa Rica. Vaccine was provided for the trial by GlaxoSmithKline Biologicals (GSK), under a Clinical Trials Agreement with the NCI. GSK also provided support for aspects of the trial associated with regulatory submission needs of the company under FDA BB-IND 7920. One or more of the authors are employed by a commercial company. These include: Mark T. Esser, MedImmune; Katie Matys, PPD Vaccines and Biologics Center of Excellence; Ariane Meuree, GlaxoSmithKline Biologicals; Wim Quint, DDL Diagnostic Laboratory; and Leen-Jan van Doorn, DDL Diagnostic Laboratory. No other financial disclosures were reported. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SWL AG CP SCM ACR M. Schiffman SW LAP RH AH M. Safaeian. Performed the experiments: CP ACR PG MTE KM TJK AM WQ LV. Analyzed the data: SWL AG SW M. Safaeian. Contributed reagents/materials/analysis tools: M. Schiffman SW NW MTE KM AM WQ LV. Wrote the paper: SWL.